Transfusion · 2026
Transfusion thresholds in apheresis: Results from a survey and focus group discussion.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Annen Kyle, Raval Jay S, Gupta Gaurav K, Paroder-Belenitsky Monika, Tanhehco Yvette C, Thibodeaux Suzanne R, Jones Jennifer M, Lu Wen, Zantek Nicole D, Helander Louise J, Zhao Yong, Kelley Walter E, Glatt Tanya, Mangwana Sadhana, Cone Sullivan Jensyn
Аннотация
BACKGROUND: Clinical practice guidelines for red blood cell (RBC) or platelet transfusion are not tailored specifically for therapeutic apheresis patients. It is unclear how provider transfusion thresholds in the peri-therapeutic apheresis period correlate with guidelines. We hypothesized that individual apheresis clinician practice would not wholly adhere to transfusion guidelines.
STUDY DESIGN AND METHODS: A large, international survey was designed, beta tested, piloted and sent to all members of the Association for the Advancement of Blood & Biotherapies (AABB) Therapeutic Apheresis Subsection (n = 459). Responses of interest were used to generate discussion points for an open, expert-moderated focus group discussion at the 2024 AABB Annual Meeting.
RESULTS: Total survey response rate was 10%, n = 47. Calculated sample size (survey responses) for 95% confidence level with a 10% margin of error was n = 80. Nonetheless, responses of interest were generated, including some responses deemed discordant with international guidelines. Five topics were discussed by the focus groups: (1) platelet transfusion thresholds, (2) transfusion methods prior to central venous catheter placement, (3) therapeutic plasma exchange platelet repletion, (4) hemoglobin transfusion threshold prior to RBC exchange, and (5) platelet transfusion threshold for initiating therapeutic plateletpheresis.
CONCLUSION: The survey results and focus group discussion, framed within current international guidelines and the literature, highlighted the need for enhancing the value of apheresis providers' clinical judgment and ability to impact institutional policies.
STUDY DESIGN AND METHODS: A large, international survey was designed, beta tested, piloted and sent to all members of the Association for the Advancement of Blood & Biotherapies (AABB) Therapeutic Apheresis Subsection (n = 459). Responses of interest were used to generate discussion points for an open, expert-moderated focus group discussion at the 2024 AABB Annual Meeting.
RESULTS: Total survey response rate was 10%, n = 47. Calculated sample size (survey responses) for 95% confidence level with a 10% margin of error was n = 80. Nonetheless, responses of interest were generated, including some responses deemed discordant with international guidelines. Five topics were discussed by the focus groups: (1) platelet transfusion thresholds, (2) transfusion methods prior to central venous catheter placement, (3) therapeutic plasma exchange platelet repletion, (4) hemoglobin transfusion threshold prior to RBC exchange, and (5) platelet transfusion threshold for initiating therapeutic plateletpheresis.
CONCLUSION: The survey results and focus group discussion, framed within current international guidelines and the literature, highlighted the need for enhancing the value of apheresis providers' clinical judgment and ability to impact institutional policies.